-
Study aim
-
Determine the effectiveness of silymarin in improving Alzheimer's patients and using it as an adjunct
-
Design
-
(There is only one group with 20 members in the study and all participants receive one kind of intervention)
Given that silymarin is currently available as a natural treatment for liver problems in the market, the study is in Phase 4.
-
Settings and conduct
-
In the Neurology Clinic of Imam Reza Hospital in Kermanshah, according to criteria of Alzheimer's patients are selected, The study compared the status of patients before receiving silymarin and after receiving silymarin.
Patients' drug regimens do not change at the time of entry, and only silymarin is added to their drug regimen.The diet is supposed to give them three tablets of 140 mg of silymarin daily for three months. Before and after receiving silymarin, the measurement of inflammatory factors IL-1β and TNF-α , is performed by ELISA kit and the MMSE test for evaluation of cognitive function in patients.
-
Participants/Inclusion and exclusion criteria
-
Patients who diagnosed with brain imaging and biochemical tests, Alzheimer's by a neurologist.
inclusion criteria: Patients diagnosed with brain imaging and biochemical tests, Alzheimer's have been approved by a neurologist.
Non-entry criteria: Epilepsy, heart failure, kidney failure, dialysis, hypothyroidism, vitamin B12 deficiency, mental illness, stroke, brain tumor, hydrocephaly, brain infections, pregnancy, excerbation of symptoms when patiants want to start silymarin
-
Intervention groups
-
Because the study is for the first time, 20 patients with Alzheimer's disease are included in a pilot study, and the study is evaluated before receiving silymarin and after receiving silymarin.
-
Main outcome variables
-
Score of cognitive function in Mini Mental State Examination;
Serum levels of TNF-α inflammatory factor;
Serum levels of IL-1β inflammatory factor